Journal: Cell
Article Title: B cells and T follicular helper cells mediate response to checkpoint inhibitors in high mutation burden mouse models of breast cancer.
doi: 10.1016/j.cell.2019.10.028
Figure Lengend Snippet: (A) RNA-seq signatures for sensitive tumors at 7 days (5mm= day 0/ treatment initiation) without or with anti-PD1/anti-CTLA4 therapy. (B) Flow cytometry results for CD8+ cells and CD4+ using memory markers (Cd44, Cd62L). (C) Flow cytometry of tumor infiltrating B cells with or without ICI therapy. On the right shows staining for B cells gated for activation markers. (D) Quantification of flow cytometry for activated B cells (B220+, Cd19+ or Cd20+, MHC II +, Cd80+ or Cd86+). (E) IHC staining for IgG-kappa chain in KPB25Luv tumors. (F) IgG binding assay showing serum-IgG binding (Fitc+) to KPB25Luv cells. (G) Quantification of Fitc+ cells in IgG binding assay for KP25Luv cells and off-target binding. (H) Quantification of Fitc+ IgG binding assay for T11-Apobec cells following reabsorption on off-target cells. In boxplots, bars signify the mean and standard deviation. The p-values are two-tailed from unmatched T-tests. All tumors collected after 7days of treatment or non-treatment.
Article Snippet: Mouse IgG2b Isotype Control (clone MPC-11) , Bioxcel , Cat: BE0086; RRID: AB_1107791.
Techniques: RNA Sequencing, Flow Cytometry, Staining, Activation Assay, Immunohistochemistry, Binding Assay, Standard Deviation, Two Tailed Test